Psychostimulants for ADHD-like symptoms in individuals with autism spectrum disorders

Expert Review of Neurotherapeutics

Volumn 12, Issue 4, 2012, Pages 461-473

  Cortese, Samuele ^a,b   Castelnau, Pierre ^b   Morcillo, Carmen ^c   Roux, Sylvie ^b   Bonnet Brilhault, Frédérique ^b  

^a NEW YORK UNIVERSITY CHILD STUDY CENTER   (United States)

^b UNIVERSITÉ DE TOURS   (France)

^c NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

attention deficit hyperactivity disorder; autism; autism spectrum disorders; hyperactivity; inattention; methylphenidate; pervasive developmental disorders; pharmacological treatment; psychostimulants

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; METHYLPHENIDATE; PEMOLINE; PLACEBO;

ABDOMINAL DISCOMFORT; ASPERGER SYNDROME; ATTENTION DEFICIT DISORDER; AUTISM; CLINICAL RESEARCH; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; EMOTIONAL DISORDER; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; MORNING DOSAGE; PEDIATRICS; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PSYCHOSOCIAL WITHDRAWAL; REVIEW; SIDE EFFECT; SLEEP DISORDER; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEIGHT REDUCTION;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DATABASES, BIBLIOGRAPHIC; HUMANS;

EID: 84860309470     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.23     Document Type: Review

References (40)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th Edition). American Psychiatric Association, Washington, DC, USA (2000).
2. Fombonne E. Epidemiology of pervasive developmental disorders. Pediatr. Res. 65, 591-598 (2009).
3. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: A systematic review and metaregression analysis. Am. J. Psychiatry 164(6), 942-948 (2007). (Pubitemid 46972911)
4. Grzadzinski R, Di MA, Brady E et al. Examining autistic traits in children with ADHD: Does the autism spectrum extend to ADHD? J. Autism Dev. Disord. 41(9), 1178-1191 (2011).
5. Murray MJ. Attention-deficit/hyperactivity disorder in the context of autism spectrum disorders. Curr. Psychiatry Rep. 12(5), 382-388 (2010).
6. Reiersen AM, Todd RD. Co-occurrence of ADHD and autism spectrum disorders: Phenomenology and treatment. Expert Rev. Neurother. 8(4), 657-669 (2008). (Pubitemid 351551016)
7. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J. Am. Acad. Child Adolesc. Psychiatry 46(7), 894-921 (2007).
8. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 339, b2700 (2009).
9. Abanilla PK, Hannahs GA, Wechsler R, Silva RR. The use of psychostimulants in pervasive developmental disorders. Psychiatr. Q. 76(3), 271-281 (2005). (Pubitemid 40922160)
10. Aman MG. Stimulant drug effects in developmental disorders and hyperactivity - toward a resolution of disparate findings. J. Autism Dev. Disord. 12(4), 385-398 (1982). (Pubitemid 13202153)
11. Aman MG, Langworthy KS. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J. Autism Dev. Disord. 30(5), 451-459 (2000). Comprehensive and detailed review on pharmacotherapy for ADHD-like symptoms in children with pervasive developmental disorders.
12. Aman MG, Farmer CA, Hollway J, Arnold LE. Treatment of inattention, overactivity, and impulsiveness in autism spectrum disorders. Child Adolesc. Psychiatr. Clin. N. Am. 17(4), 713-738, vii (2008). Comprehensive scholar review on pharmacotherapy for ADHD-like symptoms in children with autism spectrum disorders.
13. Rowles BM, Findling RL. Review of pharmacotherapy options for the treatment of attention-deficit/hyperactivity disorder (ADHD) and ADHD-like symptoms in children and adolescents with developmental disorders. Dev. Disabil. Res. Rev. 16(3), 273-282 (2010).
14. Jahromi LB, Kasari CL, McCracken JT et al. Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. J. Autism Dev. Disord. 39(3), 395-404 (2009).
15. Campbell M, Fish B, David R, Shapiro T, Collins P, Koh C. Response to triiodothyronine and dextroamphetamine: A study of preschool schizophrenic children. J. Autism Child Schizophr. 2(4), 343-358 (1972).
16. Campbell M, Small AM, Collins PJ, Friedman E, David R, Genieser N. Levodopa and levoamphetamine: A crossover study in young schizophrenic children. Curr. Ther. Res. Clin. Exp. 19(1), 70-86 (1976).
17. Posey D, McDougle C, Aman MG et al. A randomized, double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders. Neuropsychopharmacology S142-S143 (2004).
18. Research Units on Pediatric Psychopharmacology Autism Network. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch. Gen. Psychiatry 62(11), 1266-1274 (2005). The largest randomized controlled trial of methylphenidate in children with pervasive developmental disorders.
19. Birmaher B, Quintana H, Greenhill LL. Methylphenidate treatment of hyperactive autistic children. J. Am. Acad. Child Adolesc. Psychiatry 27(2), 248-251 (1988). (Pubitemid 18089217)
20. Di Martino A, Melis G, Cianchetti C, Zuddas A. Methylphenidate for pervasive developmental disorders: Safety and efficacy of acute single dose test and ongoing therapy: An open-pilot study. J. Child Adolesc. Psychopharmacol. 14(2), 207-218 (2004). (Pubitemid 38988787)
21. Ghuman JK, Aman MG, Lecavalier L et al. Randomized, placebo-controlled, crossover study of methylphenidate for attention-deficit/hyperactivity disorder symptoms in preschoolers with developmental disorders. J. Child Adolesc. Psychopharmacol. 19(4), 329-339 (2009). The only available randomized, placebo-controlled, crossover study of methylphenidate in preschool children with pervasive developmental disorders.
22. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J. Autism Dev. Disord. 30(3), 245-255 (2000).
23. Hoshino Y, Kumashiro H, Kaneko M, Takahashi Y. The effects of methylphenidate on early infantile autism and its relation to serum serotonin levels. Folia Psychiatr. Neurol. Jap. 31(4), 605-614 (1977). (Pubitemid 8306575)
24. Ishizaki A, Sugama M. Methylphenidate therapy in 141 patients with hyperkinetic disorder or with pervasive developmental disorder and hyperkinesia. No To Hattatsu 33(4), 323-328 (2001). (Pubitemid 32634474)
25. Nickels K, Katusic SK, Colligan RC, Weaver AL, Voigt RG, Barbaresi WJ. Stimulant medication treatment of target behaviors in children with autism: A population-based study. J. Dev. Behav. Pediatr. 29(2), 75-81 (2008). (Pubitemid 351535878)
26. Posey DJ, Aman MG, McCracken JT et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures. Biol. Psychiatry 61(4), 538-544 (2007). Companion paper to [18]. (Pubitemid 46185343)
27. Quintana H, Birmaher B, Stedge D et al. Use of methylphenidate in the treatment of children with autistic disorder. J. Autism Dev. Disord. 25(3), 283-294 (1995).
28. Santosh PJ, Baird G, Pityaratstian N, Tavare E, Gringras P. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: A retrospective and prospective effectiveness study. Child Care Health Dev. 32(5), 575-583 (2006). (Pubitemid 44210096)
29. Stigler KA, Desmond LA, Posey DJ, Wiegand RE, McDougle CJ. A naturalistic retrospective analysis of psychostimulants in pervasive developmental disorders. J. Child Adolesc. Psychopharmacol. 14(1), 49-56 (2004). (Pubitemid 38525953)
30. Conners CK. Conners' Rating Scales: Revised Technical Manual. Multi-Health Systems, NY, USA (1997).
31. Aman MG, Singh NN, Stewart AW, Field CJ. The aberrant behavior checklist: A behavior rating scale for the assessment of treatment effects. Am. J. Ment. Defic. 89(5), 485-491 (1985). (Pubitemid 15104762)
32. Guy W. ECDEU Assessment Manual for Psychopharmacology. Guy W (Ed.). US Department of Health, Education and Welfare, MD, USA (1976).
33. Aman MG, Tasse MJ, Rojahn J, Hammer D. The nisonger CBRF: A child behavior rating form for children with developmental disabilities. Res. Dev. Disabil. 17(1), 41-57 (1996). (Pubitemid 26030823)
34. Kanner L, Eisenberg L. Early infantile autism, 1943-1955. Psychiatr. Res. Rep. Am. Psychiatr. Assoc. 7, 55-65 (1957).
35. Werry JS. Studies on the hyperactive child. IV. An empirical analysis of the minimal brain dysfunction syndrome. Arch. Gen. Psychiatry 19(1), 9-16 (1968).
36. Conners CK. Rating scales for use in drug studies with children. Psychopharmacol. Bull. 24-29 (1973).
37. Schopler E, Reichler RJ, DeVellis RF, Daly K. Toward objective classification of childhood autism: Childhood autism rating scale (CARS). J. Autism Dev. Disord. 10(1), 91-103 (1980). (Pubitemid 10050041)
38. Overall JE, Campbell M. Behavioral assessment of psychopathology in children: Infantile autism. J. Clin. Psychol. 44(5), 708-716 (1988).
39. NIMH. Rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol. Bull. 21(4), 714-1124 (1985).
40. Arnold LE, Aman MG, Cook AM et al. Atomoxetine for hyperactivity in autism spectrum disorders: Placebo-controlled crossover pilot trial. J. Am. Acad. Child Adolesc. Psychiatry 45(10), 1196-1205 (2006). (Pubitemid 44465640)